Marken has announced plans for major expansion of clinical logistics and storage capabilities through new GMP (good-manufacturing-practice) depots in South Korea and Ukraine. The company also plans to add Genetically Modified Organism (GMO) storage capacity in Frankfurt and will add partner locations in Colombia, Taiwan, and Turkey. These changes will bring Marken’s network of GMP depots to 12 fully-owned and 12 partner depot locations.
Marken Korea’s Clinical Supply Centre will be 1,792 sq m of GMP-compliant space located near the Gimpo airport. It will operate with a Wholesale Dealers License (WDL) and is said to be operational by Q2 2020. The Ukraine depot is located within 10 km of the Boryspil International Airport, near the capital city of Kiev. It will be 1,350 sq m of GMP-compliant space and is said to be operational in 2Q 2020. The Frankfurt Clinical Supply Centre will be expanded to accommodate storage of highly sensitive GMO, human cells and gene therapies under ultra-low (-150 °C) temperatures. The storage unit will occupy space inside of Marken’s existing depot facility and is intended to be operational by Q1 2020. A new Clinical Distribution Centre near Bogota, Colombia, is also underway and will be built inside of an existing 76,000 sq ft UPS healthcare warehouse.
All products and substances handled by these depots will be managed by Marken’s Solo inventory management system. Wes Wheeler, Marken’s Chief Executive Officer, said, “we see continued demand for clinical storage and distribution in Ukraine, South Korea, Colombia, Turkey and Taiwan. We also see an increased demand for storage of substances which support cell and gene clinical trials and will continue to expand capacity as these trials begin to mature. We are committed to be a full service supplier of services to the clinical trials industry”.
The world's largest collection of global supply chain intelligence